1. Home
  2. MGIC vs CANF Comparison

MGIC vs CANF Comparison

Compare MGIC & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magic Software Enterprises Ltd.

MGIC

Magic Software Enterprises Ltd.

HOLD

Current Price

$26.49

Market Cap

990.3M

Sector

Technology

ML Signal

HOLD

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

HOLD

Current Price

$0.24

Market Cap

4.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGIC
CANF
Founded
1983
1994
Country
Israel
Israel
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
990.3M
4.8M
IPO Year
1991
N/A

Fundamental Metrics

Financial Performance
Metric
MGIC
CANF
Price
$26.49
$0.24
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$18.00
$3.25
AVG Volume (30 Days)
46.7K
1.2M
Earning Date
11-18-2025
02-03-2026
Dividend Yield
2.32%
N/A
EPS Growth
16.15
N/A
EPS
0.81
N/A
Revenue
$603,216,000.00
$560,000.00
Revenue This Year
$12.87
$461.72
Revenue Next Year
$6.23
N/A
P/E Ratio
$32.11
N/A
Revenue Growth
12.65
N/A
52 Week Low
$11.36
$0.24
52 Week High
$27.44
$2.33

Technical Indicators

Market Signals
Indicator
MGIC
CANF
Relative Strength Index (RSI) 60.04 30.42
Support Level $24.52 $0.26
Resistance Level $27.44 $0.30
Average True Range (ATR) 0.76 0.02
MACD -0.08 -0.00
Stochastic Oscillator 68.15 7.74

Price Performance

Historical Comparison
MGIC
CANF

About MGIC Magic Software Enterprises Ltd.

Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Share on Social Networks: